RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice.
RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-?B Activation and Atherogenesis in Mice. Circulation. 2021 01 12; 143(2):163-177.